The funds will be used to accelerate the development of biologics and to invest in technologies that complement and extend its antibody discovery platform. Specifically, AbCellera will use the funds to create and aggregate novel tools to propel the development of new biological modalities, from monoclonal, multispecific, and single-domain antibodies, to bioconjugates, gene-encoded biologics, and cell therapies.

The money also will be used to expand AbCellera's workforce, open a new research facility in 2021, and build a manufacturing facility that will produce biologics for clinical testing.

Current investor DCVC Bio and OrbiMed led the financing. Other investors include Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, the University of Minnesota, and Presight Capital.

Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...

AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...

Abcore develops antibodies against COVID-19
Antibody research and development firm Abcore said that it's discovered and tested a panel of functional therapeutic candidates for the treatment of COVID-19.

AbCellera secures COVID-19 drug development funding
AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic...